ES2531315T3 - Compuestos de fosfinato antivíricos - Google Patents

Compuestos de fosfinato antivíricos Download PDF

Info

Publication number
ES2531315T3
ES2531315T3 ES11190674T ES11190674T ES2531315T3 ES 2531315 T3 ES2531315 T3 ES 2531315T3 ES 11190674 T ES11190674 T ES 11190674T ES 11190674 T ES11190674 T ES 11190674T ES 2531315 T3 ES2531315 T3 ES 2531315T3
Authority
ES
Spain
Prior art keywords
alkyl
cycloalkyl
groups
halogen
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11190674T
Other languages
English (en)
Inventor
Anthony Casarez
Jianying Wang
Kleem Chaudhary
Aesop Cho
Michael Clarke
Edward Doerffler
Maria Fardis
Choung Kim
Hyungjung Pyun
Xiaoning C Sheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of ES2531315T3 publication Critical patent/ES2531315T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Un compuesto de fórmula II:**Fórmula** o una de sus sales farmacéuticamente aceptables, en el que: R1 se selecciona independientemente de H, alquilo, alquenilo, alquinilo, arilo, cicloalquilo, heterociclo, halógeno, haloalquilo, alquilsulfonamido, arilsulfonamido, -C(O)NHS(O)2- o -S(O)2-, opcionalmente sustituido con uno o más A3; R2 10 se selecciona entre, a) -C(Y1)(A3), b) alquilo(C2-10), cicloalquilo(C3-7) o alquil(C1-4)cicloalquilo-(C3-7), donde dicho cicloalquilo y alquil-cicloalquilo pueden estar opcionalmente mono, di o trisustituidos con alquilo(C1-3), o donde dicho alquilo, cicloalquilo y alquil-cicloalquilo pueden estar mono o disustituidos con sustituyentes seleccionados entre hidroxi y O-alquilo(C1-4), o donde cada uno de dichos grupos alquilo puede estar opcionalmente mono, di o trisustituido con halógeno, o donde cada uno de dichos grupos cicloalquilo puede tener 5, 6 o 7 miembros, uno o dos grupos -CH2- que no están unidos directamente entre sí pueden estar opcionalmente sustituidos por -O- de tal manera que el átomo O- está unido al átomo N al cual se une R2 mediante al menos dos átomos de C, c) fenilo, alquil(C1-3)-fenilo, heteroarilo o alquil(C1-3)-heteroarilo, donde los grupos heteroarilo son de 5 o 6 miembros que tienen de 1 a 3 heteroátomos seleccionados entre N, O y S, donde dichos grupos fenilo y heteroarilo pueden opcionalmente estar mono, di o trisustituidos con sustituyentes seleccionados entre halógeno, -OH, alquilo (C1-4), O-alquilo (C1-4), S-alquilo (C1-4), -NH2, -CF3, -NH(alquilo(C1-4)) y -N(alquilo(C1-4))2, -CONH2 y -CONH-alquilo (C1-4); y donde dicho alquilo(C1-3) puede estar opcionalmente sustituido con uno o más de halógeno; o d) -S(O)2(A3); R3 es H o alquilo (C1-6); Y1 es independientemente O, S, N(A3), N(O)(A3), N(OA3), N(O)(OA3) o N(N(A3)(A330 )); Z es O, S o NR3; Z1 se selecciona entre las siguientes estructuras:**Fórmula**
ES11190674T 2006-07-07 2007-07-06 Compuestos de fosfinato antivíricos Active ES2531315T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81948806P 2006-07-07 2006-07-07
US83290806P 2006-07-24 2006-07-24

Publications (1)

Publication Number Publication Date
ES2531315T3 true ES2531315T3 (es) 2015-03-12

Family

ID=38626760

Family Applications (2)

Application Number Title Priority Date Filing Date
ES11190674T Active ES2531315T3 (es) 2006-07-07 2007-07-06 Compuestos de fosfinato antivíricos
ES07796752T Active ES2388969T3 (es) 2006-07-07 2007-07-06 Compuestos antivirales de fosfinato

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES07796752T Active ES2388969T3 (es) 2006-07-07 2007-07-06 Compuestos antivirales de fosfinato

Country Status (19)

Country Link
US (4) US20090227491A1 (es)
EP (2) EP2422791B1 (es)
JP (3) JP2009542698A (es)
KR (1) KR20090026216A (es)
CN (1) CN102532198A (es)
AR (1) AR061840A1 (es)
AT (1) ATE554776T1 (es)
AU (1) AU2007269567B2 (es)
BR (1) BRPI0713961A2 (es)
CA (1) CA2656356C (es)
EA (1) EA018098B1 (es)
ES (2) ES2531315T3 (es)
HR (1) HRP20090076A2 (es)
IL (1) IL195489A0 (es)
MX (1) MX2009000236A (es)
NO (1) NO20090596L (es)
TW (1) TW200819460A (es)
WO (1) WO2008005565A2 (es)
ZA (1) ZA200810400B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
KR20090026216A (ko) 2006-07-07 2009-03-11 길리애드 사이언시즈, 인코포레이티드 항바이러스 포스피네이트 화합물
MX2010011306A (es) * 2008-04-15 2010-11-09 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c.
WO2010101967A2 (en) * 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
TW201111381A (en) * 2009-06-23 2011-04-01 Gilead Sciences Inc Pharmaceutical combinations useful for treating HCV
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US20110306541A1 (en) * 2010-06-10 2011-12-15 Gilead Sciences, Inc. Methods for treating hcv
WO2012087596A1 (en) * 2010-12-20 2012-06-28 Gilead Sciences, Inc. Combinations for treating hcv
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2012308295B2 (en) 2011-09-16 2017-10-26 Gilead Sciences, Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN103539831B (zh) * 2013-09-29 2016-02-03 北京林业大学 山杏α-葡萄糖苷酶抑制肽及其制备方法和用途
CN103539833B (zh) * 2013-09-29 2016-02-03 北京林业大学 高活性α-葡萄糖苷酶抑制肽及其制备方法和用途
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
ES2969239T3 (es) 2016-05-27 2024-05-17 Gilead Sciences Inc Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
EP0533833B1 (en) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorous produgs
DE69129650T2 (de) 1990-09-14 1999-03-25 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha Wirkstoffvorläufer von Phosphonaten
DE4308096A1 (de) 1993-03-13 1994-09-15 Hoechst Ag Prodrug-Derivate von Enzyminhibitoren mit Hydroxylgruppen, Verfahren zu deren Herstellung und ihre Verwendung
CA2126601A1 (en) 1993-06-29 1994-12-30 Mitsubishi Chemical Corporation Phosphonate-nucleotide ester derivatives
WO1995007920A1 (en) 1993-09-17 1995-03-23 Gilead Sciences, Inc. Nucleotide analogs
JPH07183249A (ja) * 1993-12-22 1995-07-21 Nec Yamagata Ltd イオン注入工程管理方法
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5968788A (en) * 1995-08-28 1999-10-19 Toray Industries, Inc. Method for producing folic acid
US6004977A (en) * 1996-12-27 1999-12-21 Hoechst Marion Roussel, Inc. N-(pyridinylamino) isoindolines and related compounds
DE19843360A1 (de) * 1998-09-22 2000-03-30 Hassan Jomaa Phosphororganische Verbindungen und ihre Verwendung
US6828301B2 (en) 2002-02-07 2004-12-07 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for hepatitis C viral protease inhibitors
EP1629000B1 (en) 2003-04-16 2009-02-18 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
PT1778702E (pt) * 2004-07-16 2011-10-18 Gilead Sciences Inc Compostos antivirais
WO2007001406A2 (en) 2004-10-05 2007-01-04 Chiron Corporation Aryl-containing macrocyclic compounds
EP1883402A2 (en) 2005-04-13 2008-02-06 Astex Therapeutics Limited Hydroxybenzamide derivatives and their use as inhibitors of hsp90
KR101294467B1 (ko) 2005-07-25 2013-09-09 인터뮨, 인크. C형 간염 바이러스 복제의 신규 거대고리형 억제제
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
EP1919898B1 (en) * 2005-07-29 2011-01-26 Tibotec Pharmaceuticals Macrocyclic inhibitors of hepatitis c virus
US7772183B2 (en) 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
KR20090026216A (ko) 2006-07-07 2009-03-11 길리애드 사이언시즈, 인코포레이티드 항바이러스 포스피네이트 화합물
US8293705B2 (en) 2007-12-21 2012-10-23 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
TW201111381A (en) 2009-06-23 2011-04-01 Gilead Sciences Inc Pharmaceutical combinations useful for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Also Published As

Publication number Publication date
HK1127295A1 (en) 2009-09-25
US8674088B2 (en) 2014-03-18
US7893264B2 (en) 2011-02-22
JP2012107061A (ja) 2012-06-07
JP6010640B2 (ja) 2016-10-19
EP2422791B1 (en) 2014-12-17
US20090227491A1 (en) 2009-09-10
WO2008005565A2 (en) 2008-01-10
WO2008005565A9 (en) 2009-01-29
US20080057031A1 (en) 2008-03-06
ATE554776T1 (de) 2012-05-15
CN102532198A (zh) 2012-07-04
EA200900154A1 (ru) 2009-06-30
BRPI0713961A2 (pt) 2012-11-27
US20110081314A1 (en) 2011-04-07
JP2015083605A (ja) 2015-04-30
AR061840A1 (es) 2008-09-24
EP2043658B1 (en) 2012-04-25
IL195489A0 (en) 2009-09-01
EP2422791A1 (en) 2012-02-29
MX2009000236A (es) 2009-01-23
EP2043658A2 (en) 2009-04-08
TW200819460A (en) 2008-05-01
US20110082112A1 (en) 2011-04-07
NO20090596L (no) 2009-04-01
AU2007269567B2 (en) 2012-11-08
EA018098B1 (ru) 2013-05-30
KR20090026216A (ko) 2009-03-11
CA2656356A1 (en) 2008-01-10
CA2656356C (en) 2013-04-09
JP2009542698A (ja) 2009-12-03
HRP20090076A2 (hr) 2009-05-31
ZA200810400B (en) 2011-12-28
AU2007269567A1 (en) 2008-01-10
US8586744B2 (en) 2013-11-19
WO2008005565A3 (en) 2008-05-02
ES2388969T3 (es) 2012-10-22

Similar Documents

Publication Publication Date Title
ES2531315T3 (es) Compuestos de fosfinato antivíricos
CO6251241A2 (es) Compuestos de prolina modificados con actividad anti-vhc
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
AR063331A1 (es) Derivados de biaril eter urea y composiciones farmaceuticas
ECSP066414A (es) Derivados de malonamida que bloquean la actividad de gama-secretasa
ECSP11010912A (es) Compuestos de pirrol
BR112014000465A2 (pt) catalisadores
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR084768A1 (es) Moduladores de la senda de complemento y usos de los mismos
HUP0401784A2 (hu) Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
PE20090042A1 (es) Analogos de ciclopamina
EA200970510A1 (ru) Гетеромоноциклическое соединение и его применение
AR038843A1 (es) Derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
AR050172A1 (es) Inhibidores de polimerasa viral
AR053774A1 (es) Derivados de sulfonilbencimidazol. composiciones farmaceuticas.
AR049543A1 (es) Derivados de la 1-amino-ftalazina, su preparacion y su aplicacion en terapeutica
CO6020016A1 (es) Derivados de 1,2,4,5 tetrahidro-3h-benzapezinas su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
AR086590A1 (es) Compuestos de ciclohexanona y herbicidas que los comprenden
AR051995A1 (es) Derivados de tieno-piridina como intensificadores alostericos de gaba -b
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.
CO6341610A2 (es) Compuesto heterociclilo aromatico que contiene nitrogeno.
AR070485A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica